 <h1>Granisol Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>granisetron</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about granisetron. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Granisol.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to granisetron: intravenous solution</i></p><p>Other dosage forms:</p><ul><li>transdermal patch extended release</li></ul><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, granisetron (the active ingredient contained in Granisol) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking granisetron:</p><p>
<i>Less common</i>
</p><ul>
<li>Blurred vision</li>
<li>fever</li>
<li>nervousness</li>
<li>pounding in the ears</li>
<li>slow or fast heartbeat</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Arm, back, or jaw pain</li>
<li>chest pain or discomfort</li>
<li>chest tightness or heaviness</li>
<li>confusion</li>
<li>dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>fainting</li>
<li>irregular heartbeat</li>
<li>nausea</li>
<li>shortness of breath</li>
<li>skin rash, hives, and itching</li>
<li>sweating</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of granisetron may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Abdominal or stomach pain</li>
<li>diarrhea</li>
<li>difficulty having a bowel movement (stool)</li>
<li>headache</li>
<li>lack or loss of strength</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Agitation</li>
<li>dizziness</li>
<li>drowsiness</li>
<li>fear</li>
<li>heartburn</li>
<li>indigestion</li>
<li>sleepiness or unusual drowsiness</li>
<li>sour stomach</li>
<li>trouble with sleeping</li>
<li>unusual taste in the mouth</li>
</ul><p>
<div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to granisetron: intravenous solution, oral solution, oral tablet, subcutaneous suspension extended release, transdermal film extended release</i></p><h3>General</h3><p>ORAL: The most commonly reported side effects included headache, constipation, and asthenia.</p>
<p></p>
<p>PARENTERAL: The most commonly reported side effects included injection site reactions, constipation, headache, and diarrhea.</p>
<p></p>
<p>TRANSDERMAL: The most commonly reported side effects included constipation, QT prolongation, and headache.<sup>[Ref]</sup></p><h3>Local</h3><p>PARENTERAL:</p>
<p><b>Very common</b> (10% or more): Any injection site reactions (up to 62%), bruising/hematoma (up to 45%), tenderness (up to 27%), pain (up to 20%), mass/nodule (up to 18%), erythema/redness (up to 17%)</p>
<p><b>Common</b> (1% to 10%): Bleeding, induration/swelling, infection at injection site, other</p>
<p><b>Frequency not reported</b>: Discoloration, irritation, lipoma, paresthesia, pruritus, rash, reaction, scab, scar, vesicles, warmth</p>
<p></p>
<p>TRANSDERMAL:</p>
<p><b>Uncommon</b> (0.1% to 1%): Application site irritation</p>
<p><b>Frequency not reported</b>: Application site erythema, application site pain, application site pruritus, application site rash, application site reactions</p>
<p><b>Postmarketing reports</b>: Application site burn, application site discoloration, application site urticaria, application site vesicles, patch non-adhesion<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>ORAL:</p>
<p><b>Very common</b> (10% or more): Nausea (up to 20%), constipation (up to 18%), vomiting (up to 12%)</p>
<p><b>Common</b> (1% to 10%): Abdominal pain, diarrhea, dyspepsia</p>
<p></p>
<p>PARENTERAL:</p>
<p><b>Very common</b> (10% or more): Constipation (up to 22%)</p>
<p><b>Common</b> (1% to 10%): Abdominal pain, diarrhea, dyspepsia, gastroesophageal reflux</p>
<p><b>Frequency not reported</b>: Pancreatitis</p>
<p></p>
<p>TRANSDERMAL:</p>
<p><b>Common</b> (1% to 10%): Constipation</p>
<p><b>Uncommon</b> (0.1% to 1%): Dry mouth, nausea, retching</p>
<p><b>Frequency not reported</b>: Abdominal pain, diarrhea, vomiting<sup>[Ref]</sup></p><h3>Nervous system</h3><p>ORAL:</p>
<p><b>Very common</b> (10% or more): Headache (up to 21%)</p>
<p><b>Common</b> (1% to 10%): Central nervous system (CNS) stimulation, dizziness, somnolence, taste disorder</p>
<p><b>Uncommon</b> (0.1% to 1%): Serotonin syndrome</p>
<p><b>Rare</b> (0.01% to 0.1%): Extrapyramidal syndrome, syncope</p>
<p><b>Frequency not reported</b>: Autonomic dysfunction, extrapyramidal symptoms, neuromuscular abnormalities</p>
<p></p>
<p>PARENTERAL:</p>
<p><b>Very common</b> (10% or more): Headache (up to 14%)</p>
<p><b>Common</b> (1% to 10%): CNS stimulation, dizziness, somnolence, taste disorder</p>
<p><b>Uncommon</b> (0.1% to 1%): Extrapyramidal reactions, serotonin syndrome</p>
<p><b>Rare</b> (0.01% to 0.1%): Extrapyramidal syndrome, syncope</p>
<p></p>
<p>TRANSDERMAL:</p>
<p><b>Uncommon</b> (0.1% to 1%): Headache, vertigo</p>
<p><b>Rare</b> (0.01% to 0.1%): Dyskinesia, dystonia</p>
<p><b>Frequency not reported</b>: Dizziness, extrapyramidal reactions, somnolence, syncope<sup>[Ref]</sup></p><p>Drug-induced headache is generally mild.  In clinical trials, headache typically resolved spontaneously or was relieved by analgesics.<sup>[Ref]</sup></p><h3>Other</h3><p>ORAL:</p>
<p><b>Very common</b> (10% or more): Asthenia (up to 18%)</p>
<p><b>Common</b> (1% to 10%): Fever</p>
<p></p>
<p>PARENTERAL:</p>
<p><b>Very common</b> (10% or more): Fatigue (up to 21%)</p>
<p><b>Common</b> (1% to 10%): Asthenia, fever</p>
<p></p>
<p>TRANSDERMAL:</p>
<p><b>Frequency not reported</b>: Asthenia, fever<sup>[Ref]</sup></p><h3>Hepatic</h3><p>ORAL:</p>
<p><b>Common</b> (1% to 10%): ALT elevation, AST elevation, elevated hepatic transaminases, transient ALT increases, transient AST increases</p>
<p></p>
<p>PARENTERAL:</p>
<p><b>Common</b> (1% to 10%): ALT elevation, AST elevation, transaminases increased, transient ALT increases, transient AST increases</p>
<p><b>Frequency not reported</b>: Elevation of serum transaminase levels</p>
<p></p>
<p>TRANSDERMAL:</p>
<p><b>Uncommon</b> (0.1% to 1%): ALT increased, AST increased, GGT increased</p>
<p><b>Frequency not reported</b>: Elevated hepatic transaminases<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>ORAL:</p>
<p><b>Common</b> (1% to 10%): Agitation, anxiety, insomnia</p>
<p><b>Frequency not reported</b>: Altered mental status</p>
<p></p>
<p>PARENTERAL:</p>
<p><b>Common</b> (1% to 10%): Agitation, anxiety, insomnia</p>
<p></p>
<p>TRANSDERMAL:</p>
<p><b>Frequency not reported</b>: Anxiety, insomnia<sup>[Ref]</sup></p><h3>Hematologic</h3><p>ORAL:</p>
<p><b>Common</b> (1% to 10%): Anemia, leukopenia, thrombocytopenia</p>
<p></p>
<p>PARENTERAL:</p>
<p><b>Common</b> (1% to 10%): Anemia, leukopenia, thrombocytopenia</p>
<p></p>
<p>TRANSDERMAL:</p>
<p><b>Frequency not reported</b>: Anemia, leukopenia, thrombocytopenia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>ORAL:</p>
<p><b>Common</b> (1% to 10%): Alopecia</p>
<p><b>Uncommon</b> (0.1% to 1%): Rash/skin rashes, urticaria</p>
<p></p>
<p>PARENTERAL:</p>
<p><b>Common</b> (1% to 10%): Alopecia, rash/skin rashes</p>
<p><b>Uncommon</b> (0.1% to 1%): Urticaria</p>
<p></p>
<p>TRANSDERMAL:</p>
<p><b>Frequency not reported</b>: Alopecia, rash, urticaria<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>ORAL:</p>
<p><b>Common</b> (1% to 10%): Hypertension</p>
<p><b>Uncommon</b> (0.1% to 1%): QT prolongation</p>
<p><b>Rare</b> (0.01% to 0.1%): Angina pectoris, arrhythmias, atrial fibrillation, ECG abnormalities, hypotension, non-sustained tachycardia, sinus bradycardia, varying degrees of atrioventricular (AV) block, ventricular ectopy</p>
<p></p>
<p>PARENTERAL:</p>
<p><b>Common</b> (1% to 10%): Hypertension</p>
<p><b>Uncommon</b> (0.1% to 1%): QT prolongation</p>
<p><b>Rare</b> (0.01% to 0.1%): Angina pectoris, arrhythmias, atrial fibrillation, ECG abnormalities, hypotension, non-sustained tachycardia, sinus bradycardia, varying degrees of AV block, ventricular ectopy</p>
<p><b>Frequency not reported</b>: Flushing</p>
<p><b>Postmarketing reports</b>: Bradycardia, chest pain, palpitations, sick sinus syndrome</p>
<p></p>
<p>TRANSDERMAL:</p>
<p><b>Common</b> (1% to 10%): QT prolongation</p>
<p><b>Uncommon</b> (0.1% to 1%): Flushing, generalized edema</p>
<p><b>Rare</b> (0.01% to 0.1%): Angina pectoris, atrial fibrillation, hypertension, hypotension</p>
<p><b>Postmarketing reports</b>: Bradycardia, chest pain, palpitations, sick sinus syndrome<sup>[Ref]</sup></p><h3>Metabolic</h3><p>ORAL:</p>
<p><b>Common</b> (1% to 10%): Decreased appetite</p>
<p></p>
<p>PARENTERAL:</p>
<p><b>Common</b> (1% to 10%): Decreased appetite</p>
<p></p>
<p>TRANSDERMAL:</p>
<p><b>Uncommon</b> (0.1% to 1%): Decreased appetite<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>ORAL:</p>
<p><b>Uncommon</b> (0.1% to 1%): Anaphylaxis, hypersensitivity reactions</p>
<p><b>Rare</b> (0.01% to 0.1%): Severe hypersensitivity reactions</p>
<p></p>
<p>PARENTERAL:</p>
<p><b>Uncommon</b> (0.1% to 1%): Anaphylaxis, hypersensitivity reactions</p>
<p></p>
<p>TRANSDERMAL:</p>
<p><b>Frequency not reported</b>: Anaphylaxis, hypersensitivity reactions/severe hypersensitivity reactions<sup>[Ref]</sup></p><h3>Respiratory</h3><p>ORAL:</p>
<p><b>Uncommon</b> (0.1% to 1%): Shortness of breath</p>
<p></p>
<p>PARENTERAL:</p>
<p><b>Rare</b> (0.01% to 0.1%): Shortness of breath</p>
<p></p>
<p>TRANSDERMAL:</p>
<p><b>Rare</b> (0.01% to 0.1%): Shortness of breath<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>TRANSDERMAL:</p>
<p><b>Uncommon</b> (0.1% to 1%): Arthralgia<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Kytril (granisetron)." SmithKline Beecham, Philadelphia, PA. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_4">4. "Product Information. Sancuso (granisetron)." ProStrakan Group, Bedminster, NJ. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about Granisol (granisetron)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: 5HT3 receptor antagonists</li>
</ul>
<h3>Consumer resources</h3>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Kytril, Sancuso, Sustol</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Nausea/Vomiting, Chemotherapy Induced</li>
<li>Nausea/Vomiting, Postoperative</li>
<li>Nausea/Vomiting, Radiation Induced</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to granisetron: intravenous solution, oral solution, oral tablet, subcutaneous suspension extended release, transdermal film extended release</i></p><h3>General</h3><p>ORAL: The most commonly reported side effects included headache, constipation, and asthenia.</p><p></p><p>PARENTERAL: The most commonly reported side effects included injection site reactions, constipation, headache, and diarrhea.</p><p></p><p>TRANSDERMAL: The most commonly reported side effects included constipation, QT prolongation, and headache.<sup>[Ref]</sup></p><h3>Local</h3><p>PARENTERAL:</p><p><b>Very common</b> (10% or more): Any injection site reactions (up to 62%), bruising/hematoma (up to 45%), tenderness (up to 27%), pain (up to 20%), mass/nodule (up to 18%), erythema/redness (up to 17%)</p><p><b>Common</b> (1% to 10%): Bleeding, induration/swelling, infection at injection site, other</p><p><b>Frequency not reported</b>: Discoloration, irritation, lipoma, paresthesia, pruritus, rash, reaction, scab, scar, vesicles, warmth</p><p></p><p>TRANSDERMAL:</p><p><b>Uncommon</b> (0.1% to 1%): Application site irritation</p><p><b>Frequency not reported</b>: Application site erythema, application site pain, application site pruritus, application site rash, application site reactions</p><p><b>Postmarketing reports</b>: Application site burn, application site discoloration, application site urticaria, application site vesicles, patch non-adhesion<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>ORAL:</p><p><b>Very common</b> (10% or more): Nausea (up to 20%), constipation (up to 18%), vomiting (up to 12%)</p><p><b>Common</b> (1% to 10%): Abdominal pain, diarrhea, dyspepsia</p><p></p><p>PARENTERAL:</p><p><b>Very common</b> (10% or more): Constipation (up to 22%)</p><p><b>Common</b> (1% to 10%): Abdominal pain, diarrhea, dyspepsia, gastroesophageal reflux</p><p><b>Frequency not reported</b>: Pancreatitis</p><p></p><p>TRANSDERMAL:</p><p><b>Common</b> (1% to 10%): Constipation</p><p><b>Uncommon</b> (0.1% to 1%): Dry mouth, nausea, retching</p><p><b>Frequency not reported</b>: Abdominal pain, diarrhea, vomiting<sup>[Ref]</sup></p><h3>Nervous system</h3><p>ORAL:</p><p><b>Very common</b> (10% or more): Headache (up to 21%)</p><p><b>Common</b> (1% to 10%): Central nervous system (CNS) stimulation, dizziness, somnolence, taste disorder</p><p><b>Uncommon</b> (0.1% to 1%): Serotonin syndrome</p><p><b>Rare</b> (0.01% to 0.1%): Extrapyramidal syndrome, syncope</p><p><b>Frequency not reported</b>: Autonomic dysfunction, extrapyramidal symptoms, neuromuscular abnormalities</p><p></p><p>PARENTERAL:</p><p><b>Very common</b> (10% or more): Headache (up to 14%)</p><p><b>Common</b> (1% to 10%): CNS stimulation, dizziness, somnolence, taste disorder</p><p><b>Uncommon</b> (0.1% to 1%): Extrapyramidal reactions, serotonin syndrome</p><p><b>Rare</b> (0.01% to 0.1%): Extrapyramidal syndrome, syncope</p><p></p><p>TRANSDERMAL:</p><p><b>Uncommon</b> (0.1% to 1%): Headache, vertigo</p><p><b>Rare</b> (0.01% to 0.1%): Dyskinesia, dystonia</p><p><b>Frequency not reported</b>: Dizziness, extrapyramidal reactions, somnolence, syncope<sup>[Ref]</sup></p><p>Drug-induced headache is generally mild.  In clinical trials, headache typically resolved spontaneously or was relieved by analgesics.<sup>[Ref]</sup></p><h3>Other</h3><p>ORAL:</p><p><b>Very common</b> (10% or more): Asthenia (up to 18%)</p><p><b>Common</b> (1% to 10%): Fever</p><p></p><p>PARENTERAL:</p><p><b>Very common</b> (10% or more): Fatigue (up to 21%)</p><p><b>Common</b> (1% to 10%): Asthenia, fever</p><p></p><p>TRANSDERMAL:</p><p><b>Frequency not reported</b>: Asthenia, fever<sup>[Ref]</sup></p><h3>Hepatic</h3><p>ORAL:</p><p><b>Common</b> (1% to 10%): ALT elevation, AST elevation, elevated hepatic transaminases, transient ALT increases, transient AST increases</p><p></p><p>PARENTERAL:</p><p><b>Common</b> (1% to 10%): ALT elevation, AST elevation, transaminases increased, transient ALT increases, transient AST increases</p><p><b>Frequency not reported</b>: Elevation of serum transaminase levels</p><p></p><p>TRANSDERMAL:</p><p><b>Uncommon</b> (0.1% to 1%): ALT increased, AST increased, GGT increased</p><p><b>Frequency not reported</b>: Elevated hepatic transaminases<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>ORAL:</p><p><b>Common</b> (1% to 10%): Agitation, anxiety, insomnia</p><p><b>Frequency not reported</b>: Altered mental status</p><p></p><p>PARENTERAL:</p><p><b>Common</b> (1% to 10%): Agitation, anxiety, insomnia</p><p></p><p>TRANSDERMAL:</p><p><b>Frequency not reported</b>: Anxiety, insomnia<sup>[Ref]</sup></p><h3>Hematologic</h3><p>ORAL:</p><p><b>Common</b> (1% to 10%): Anemia, leukopenia, thrombocytopenia</p><p></p><p>PARENTERAL:</p><p><b>Common</b> (1% to 10%): Anemia, leukopenia, thrombocytopenia</p><p></p><p>TRANSDERMAL:</p><p><b>Frequency not reported</b>: Anemia, leukopenia, thrombocytopenia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>ORAL:</p><p><b>Common</b> (1% to 10%): Alopecia</p><p><b>Uncommon</b> (0.1% to 1%): Rash/skin rashes, urticaria</p><p></p><p>PARENTERAL:</p><p><b>Common</b> (1% to 10%): Alopecia, rash/skin rashes</p><p><b>Uncommon</b> (0.1% to 1%): Urticaria</p><p></p><p>TRANSDERMAL:</p><p><b>Frequency not reported</b>: Alopecia, rash, urticaria<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>ORAL:</p><p><b>Common</b> (1% to 10%): Hypertension</p><p><b>Uncommon</b> (0.1% to 1%): QT prolongation</p><p><b>Rare</b> (0.01% to 0.1%): Angina pectoris, arrhythmias, atrial fibrillation, ECG abnormalities, hypotension, non-sustained tachycardia, sinus bradycardia, varying degrees of atrioventricular (AV) block, ventricular ectopy</p><p></p><p>PARENTERAL:</p><p><b>Common</b> (1% to 10%): Hypertension</p><p><b>Uncommon</b> (0.1% to 1%): QT prolongation</p><p><b>Rare</b> (0.01% to 0.1%): Angina pectoris, arrhythmias, atrial fibrillation, ECG abnormalities, hypotension, non-sustained tachycardia, sinus bradycardia, varying degrees of AV block, ventricular ectopy</p><p><b>Frequency not reported</b>: Flushing</p><p><b>Postmarketing reports</b>: Bradycardia, chest pain, palpitations, sick sinus syndrome</p><p></p><p>TRANSDERMAL:</p><p><b>Common</b> (1% to 10%): QT prolongation</p><p><b>Uncommon</b> (0.1% to 1%): Flushing, generalized edema</p><p><b>Rare</b> (0.01% to 0.1%): Angina pectoris, atrial fibrillation, hypertension, hypotension</p><p><b>Postmarketing reports</b>: Bradycardia, chest pain, palpitations, sick sinus syndrome<sup>[Ref]</sup></p><h3>Metabolic</h3><p>ORAL:</p><p><b>Common</b> (1% to 10%): Decreased appetite</p><p></p><p>PARENTERAL:</p><p><b>Common</b> (1% to 10%): Decreased appetite</p><p></p><p>TRANSDERMAL:</p><p><b>Uncommon</b> (0.1% to 1%): Decreased appetite<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>ORAL:</p><p><b>Uncommon</b> (0.1% to 1%): Anaphylaxis, hypersensitivity reactions</p><p><b>Rare</b> (0.01% to 0.1%): Severe hypersensitivity reactions</p><p></p><p>PARENTERAL:</p><p><b>Uncommon</b> (0.1% to 1%): Anaphylaxis, hypersensitivity reactions</p><p></p><p>TRANSDERMAL:</p><p><b>Frequency not reported</b>: Anaphylaxis, hypersensitivity reactions/severe hypersensitivity reactions<sup>[Ref]</sup></p><h3>Respiratory</h3><p>ORAL:</p><p><b>Uncommon</b> (0.1% to 1%): Shortness of breath</p><p></p><p>PARENTERAL:</p><p><b>Rare</b> (0.01% to 0.1%): Shortness of breath</p><p></p><p>TRANSDERMAL:</p><p><b>Rare</b> (0.01% to 0.1%): Shortness of breath<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>TRANSDERMAL:</p><p><b>Uncommon</b> (0.1% to 1%): Arthralgia<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Kytril (granisetron)." SmithKline Beecham, Philadelphia, PA. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_4">4. "Product Information. Sancuso (granisetron)." ProStrakan Group, Bedminster, NJ. </p><h2>More about Granisol (granisetron)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: 5HT3 receptor antagonists</li>
</ul><h3>Consumer resources</h3><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Nausea/Vomiting, Chemotherapy Induced</li>
<li>Nausea/Vomiting, Postoperative</li>
<li>Nausea/Vomiting, Radiation Induced</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>